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Abstract: Background: The long non-coding RNA (lncRNA) growth arrest–specific transcript 5
(GAS5) seems to be involved in the regulation of mediators of tissue injury, in particular matrix
metalloproteinases (MMPs), implicated in the pathogenesis of inflammatory bowel disease (IBD). We
investigated the role of GAS5 in regulatingMMP2 andMMP9 expression in pediatric patients with
IBD and in vitro. Methods: In total, 25 IBD patients were enrolled: For each patient paired inflamed
and non-inflamed biopsies were collected. RNA was extracted and GAS5,MMP2, andMMP9were
quantified by TaqMan assay. The expression of GAS5 and MMPs was also determined in the human
monocytic THP1 cells di↵erentiated into macrophages and stimulated with lipopolysaccharide (LPS).
The function of GAS5was assessed by overexpressing the lncRNA and evaluating the MMPs levels.
Results: Real-time PCR results demonstrated a downregulation of GAS5 and an upregulation of
both MMPs in inflamed tissues. In vitro data confirmed the trend observed in patients for the three
genes: The stimulation with LPS promoted a downregulation of GAS5while an increase of MMPs
was observed. Overexpression experiments showed that higher levels of GAS5 lead to a decrease of
both enzymes. Conclusion: These results provide new information about the role of GAS5 in IBD:
The lncRNA could mediate tissue damage by modulating the expression of MMPs.
Keywords: inflammatory bowel disease; long non-coding-RNA; GAS5;MMP2;MMP9
1. Introduction
Inflammatory bowel disease (IBD) includes two di↵erent pathologies, Crohn’s disease (CD)
and ulcerative colitis (UC), that, although di↵erent in their pathogenesis, show common clinical
characteristics such as chronic inflammation at di↵erent levels of the gastrointestinal tract and a
dysregulated excessive immune response [1]. Both CD and UC are characterized by chronic changes
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in the intestinal tissues, consisting of an intense infiltration of lymphocytes and plasma cells and
deep remodeling of the connective tissue, leading to increased turnover of extracellular matrix (ECM)
components [2]. Disturbance of the balance between the synthesis and degradation of ECM elements
may result in progressive intestinal barrier destruction.
Degradation of ECM components is tightly controlled by the enzymatic activity of matrix
metalloproteinases (MMPs), proteins that play an important role in the pathogenesis of IBD [3]. MMPs
are secreted as pro-enzymes and require cleavage of the pro-peptide to become active. Increased levels
of these proteins in the intestinal mucosa of IBD patients have been reported: The epithelial-derived
MMP9 is an important mediator of tissue injury in colitis, whereas MMP2 maintains gut barrier
function, favoring infiltration processes of leukocytes in inflamed tissue [4–8].
Longnon-codingRNAs (lncRNAs)haveemergedas importantgeneexpression regulatoryelements and
recent data have implicated the deregulated expression of certain lncRNA networks in the pathogenesis of
autoimmuneand inflammatorydiseases, such as IBD [9–11]. In this context, one of themost studied lncRNAs
is growth arrest–specific transcript 5 (GAS5).GAS5 can be deregulated by different pro-inflammatory stimuli
in vitro [12–14]. Moreover, GAS5 attenuates the expression and the activity ofMMP2 andMMP9 and has a
role in regulating the metastasis phenotype of melanoma cells [15,16]; however, no data are published about
the role of GAS5 as a regulator ofMMP9 andMMP2 expression in IBD patients.
In the present study, our research focused on the potential role of GAS5 in regulating the
transcription of MMP2 and MMP9, starting from their evaluation in inflamed and non-inflamed
colonic tissues of pediatric patients with IBD. Moreover, considering that activated monocytes and
macrophages are the major contributors of MMP9 and MMP2 in inflammatory diseases [17,18],
an in vitro study on these cellular models was done to investigate the association between GAS5 and
the two MMPs’ expression.
2. Results
2.1. Patients
Twenty-five children with IBD (CD 13; UC 12) were enrolled at diagnosis in this study and their
baseline characteristics and histologic findings are shown in Table 1.
Table 1. Characteristics and histologic scores of the patients.
Patients (n) 25
Age (mean, range) 12.5, 6.2–18
Male (%) 13 (52%)
CD (%) 13 (52%)
UC (%) 12 (48%)
Clinical score:
PCDAI 1 (mean, range) 30.6, 7.5–55
PUCAI 2 (mean, range) 30.1, 10–75
Histologic findings:
Inflammation score Score (% of patients)
0 (0%)
1 (4%)
2 (24%)
3 (36%)
4 (28%)
5 (8%)
Architectural score Score (% of patients)
0 (0%)
1 (8%)
2 (28%)
3 (52%)
4 (12%)
1 Pediatric Crohn’s Disease Activity Index; 2 Pediatric Ulcerative Colitis Activity Index.
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2.2. GAS5 Expression in Mucosal Biopsies of Pediatric IBD Patients
For each patient, during colonoscopy, an inflamed and a non-inflamed biopsy was collected in
TRIzol reagent. GAS5 gene relative expression was evaluated, showing a statistically significant
downregulation in inflamed mucosa in comparison to the non-inflamed one (Figure 1 and
supplementary Table S1).
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GAS5 Correlation with Disease Activity Scores
Interestingly, GAS5 level were negatively associated with the clinical scores reported in Table 1.
No significant association was found with the inflammation and architectural parameters (Figure 2).
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test p = 0.048; r =  0.40.
2.3. MMP2 and MMP9 Gene and Protein Expression in Colon Biopsies of Pediatric IBD Patients
Gene and protein expression analyses were performed to study the relation between the enzymes
and GAS5 in colon biopsies of pediatric patients with IBD at diagnosis. Real-time PCR results
demonstrated an increased expression of both MMPs in inflamed tissues (Figure 3 and supplementary
Table S1).
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Figure 4. MMP2 (74 kDa; A and B) and MMP9 (92 kDa; A and C) protein expression in colon biopsies
of IBD pediatric patients analyzed by immunoblotting. Protein lysates were obtained from inflamed
(INF) and non-inflamed (NON-INF) tissues. Actin (42 kDa) was used as internal loading control.
Representative western blot reflectingMMP2,MMP9 and actin protein levels. Paired t test * p < 0.05.
2.4. GAS5, MMP2, and MMP9 Gene Expression in the THP1 Cell Line
The THP1 human monocytic cell line was chosen as the cellular model to confirm the involvement
of GAS5 in the regulation ofMMP2 andMMP9 expression. Experiments were conducted at di↵erent
stages of di↵erentiation, from monocyte (THP1) to macrophages (THP1 + PMA (phorbol-12-myristate
13-acetate)). The e↵ects of stimulation by LPSwas also tested. Real-time PCR results of GAS5 expression
showed a downregulation of its levels in stimulated cells compared to unstimulated THP1. A decrease
of GAS5 was also evident in PMA-di↵erentiated macrophages compared to monocytes, while LPS
treatment did not further reduce GAS5 expression (Figure 5).
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Figure 5. Relative expression (RE, values are expressed as 2 DCt) ofGAS5 (A),MMP2 (B), andMMP9 (C)
in THP1 cells exposed to LPS (lipopolysaccharide), PMA (phorbol-12-myristate 13-acetate), and PMA
+ LPS. GAS5, MMP2, and MMP9 expression was normalized using 18S gene. One-way ANOVA
GAS5 p = 0.003,MMP2 p= 0.018,MMP9 p< 0.0001 Bonfer oni’smultiple comparison post-test * p < 0.05,
** p < 0.01, *** p < 0.001.
MMP2 andMMP9 expression levels increased in stimulated cells, particularly in PMA-differentiated
macrophages, with a similar trend for both MMPs (Figure 5), confirming the trend observed in patients.
2.5. MMP2 and MMP9 Gene Expression in Cells Transfected with the pcDNA3.1-GAS5 Plasmid
Following the transient transfection with pcDNA-GAS5 plasmid, the e ciency of the
overexpression of the lncRNA on both monocyte (THP1) and macrophages (THP1 + PMA) was
assessed by real-time PCR (Figure 6).
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Figure 6. Evaluation of GAS5 levels after transfection with pcDNA-GAS5 plasmid in monocytes
(GAS5_MONO) and macrophages (GAS5_MACRO). GAS5 expression was normalized using GAPDH
gene and relative expression (RE) values are expressed as 2 DCt. One-way ANOVA GAS5 p = 0.0005,
Bonferroni’s multiple comparison p st-test ** p < 0.01, *** p < 0.001.
Real-timePCRresults ofMMP2andMMP9expression, reported inFigure7, showedadownregulation
in LPS-stimulat d monocytes and macrophages compared with the respective control tran fected with
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the empty vector, demonstrating the involvement of the lncRNA in the regulation of gene expression
of the two MMPs.
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Figure 7. Levels of MMP2 (A) and MMP9 (B) after overexpression of GAS5 (GAS5) in monocyte
stimulated with LPS (LPS) and macrophages stimulated with LPS (PMA + LPS) and in controls
(EMPTY). MMP2 and MMP9 expression were normalized using GAPDH gene and relative expression
(RE) values are expressed as 2 DDCt. Two-way ANOVA: EMPTY vs. GAS5 MMP2 p = 0.002, MMP9
p < 0.0001 Bonferroni’s multiple comp rison post-test * p < 0.05, ** p < 0.01, *** p < 0.001.
2.6. MMP2 and MMP9 Proteins Released by THP1 Cells Overexpressing GAS5
To confirm the role of GAS5 in regulating the expression ofMMP2 andMMP9, their levels in the
supernatant of both LPS-stimulated monocytes and PMA-differentiated macrophages overexpressing
GAS5 were evaluated by enzyme-linked immunosorbent assay (ELISA) test. As reported in Figure 8,
MMP9was less expressed in GAS5-transfected monocytes with respect to the control; no difference was
detected measuring MMP2 levels. Overexpressing GAS5 significantly downregulated both MMP proteins
in macrophages stimulated with LPS compared to the cells transfected with the empty vector (Figure 8).
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3. Discussion
In IBD pediatric patients, genetic and environmental factors are responsible for the alteration in
the epithelial barrier; the activity of pro-inflammatory elements released from macrophages, T cells,
and innate lymphoid cells is also important [19]. MMPs have a key role in this context: In addition to
playing a central role in ECM turnover, they activate or degrade a variety of other substrates including
chemokines, cytokines, growth factors, and junctional proteins [20].
Several studies have shown thatMMP2 andMMP9 are highly expressed in IBD inflamed colonic
mu sa, serum, urin , and fecal s mpl s [7,21–23]. However, the molecular mechanis by which the
levels of these enzymes can be modulated during he inflammatory response still remains unclear.
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Recently, it has been suggested that lncRNAs may play an important role in the pathophysiology
of IBD, and many researches have therefore covered this topic. Forty-seven lncRNAs dysregulated in
IBD were identified, and, even though their exact role requires more studies, it has been suggested that
they might have a crucial role in the regulation of inflammatory pathways [24].
The present study explores the role of the lncRNAGAS5 as a regulator of two important mediators
of inflammatory response in IBD: MMP2 and the MMP9. In particular, we evaluated the expression of
GAS5,MMP2, andMMP9 in biopsies of drug-naïve patients with CD and UC. Our results showed
that the expression of the lncRNA in patients with IBD was lower in inflamed tissues compared to the
adjacent normal part, while the expression levels ofMMP2 andMMP9 increased in inflamed biopsies,
confirming previously published results [3–5,22,23].
As reported in the literature, GAS5 seems to play a role in various inflammatory and autoimmune
diseases such as rheumatoid arthritis and systemic lupus erythematosus in which significantly reduced
GAS5 levels in immune cells were shown [25,26]. Moreover, the lncRNA is di↵erently expressed
in pediatric patients with IBD treated with glucocorticoids and positively correlates with steroid
resistance, suggesting a role of GAS5 in the modulation of drug e cacy [27].
Preliminary data have already shown that GAS5 is involved in the regulation of these two MMPs,
indeed Chen et al. have shown that the expression of MMP2 and MMP9 is inversely correlated with
the levels of the lncRNA GAS5 in melanoma cells [15]. Overexpression of GAS5 reduced the levels of
the proteins whereas the knockdown increased their expression [15].
Our work is the first report in which the potential role of GAS5 in the regulation of MMPs in IBD
patients is described. Interestingly, data obtained from our cohort highlight a negative correlation
between GAS5 levels and the clinical scores PUCAI (Pediatric Crohn’s Disease Activity Index) and
PCDAI (Pediatric Ulcerative Colitis Activity Index). These scores currently are the most rigorously
developed non-invasive disease activity indexes in the field of childhood IBD, combining subjective
reporting of the degree of abdominal pain, stool pattern, and general well-being and laboratory test
results (hematocrit, erythrocyte sedimentation rate, and serum albumin) into a single score. PUCAI and
PCDAI scores are significantly higher in patients with active disease while a score of <10 is consistent
with inactive disease [28]. Endoscopy and clinical indexes are not always perfectly correlated because
some symptoms are not related to the mucosal inflammation: GAS5 levels could be a specific molecular
marker useful to better predict disease activity and stratify the severity of the disease. This result
further highlights the need to investigate the potential function of GAS5 in IBD pathogenesis and
progression. Currently, significant correlations between two lncRNAs quantified in the ileum of CD
patients, LINC01272 and HNF4A-AS1, and more severe mucosal injury were found, but no correlation
with clinical disease activities has been reported [29]. Di↵erently, for GAS5, no correlation was found
with endoscopic and inflammation scores in our cohort of patients; however, the clinical score was also
not associated with these parameters in our study, as already described [30].
Considering that remodeling of the ECM and cell surface by MMPs is one of the most important
function of monocytes and macrophages we decided to investigate the role of GAS5 in the regulation
of MMP expression in the THP1 monocyte cell line. In particular, in vitro experiments at di↵erent
stages of di↵erentiation, from monocyte to macrophages, stimulated with a proinflammatory factor
were conducted. The results confirmed the trend observed in patients for the three genes: Stimulation
with LPS promotes a downregulation of GAS5 in both monocytes and macrophages, while an
increase ofMMPswas observed. This data highlight that, in response to immune activation, GAS5 is
transcriptionally repressed but the mechanism involved needs to be further investigated.
We thus studied the e↵ects of GAS5-overexpression on the production of MMPs in response to
LPS stimulation in terms of gene and protein expression. Forced expression of GAS5 in monocytes and
macrophages stimulated with LPS led to a reduction of levels of MMPs in both RNA and proteins,
supporting the role of GAS5 in modulating their expression, probably at the transcriptional level.
It would be interesting to evaluate in our cellular model whether the reduced expression of GAS5
could induce an increase ofMMP2 andMMP9 expression as already reported in other cells [15].
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It is well known that lncRNAs can regulate gene expression at the epigenetic, transcription,
RNA processing, and translation levels [31]. The presence of GAS5 both in the cytoplasm and the
nucleus was confirmed in our previous study [27]. Functional studies have demonstrated that GAS5
suppresses transcription by recruiting the histone methyltransferase polycomb repressive complex
2 to the promoter region of target genes, inhibiting gene expression [32]; further interaction studies
by means of chromatin immunoprecipitation should be focused on this pathway to demonstrate the
molecular mechanism by which GAS5 regulates MMPs transcription.
Moreover, GAS5 seems to have a protective role during the induction of inflammation:
Its upregulation repressed the MMPs, acting as an anti-inflammatory agent. Actually, only one
paper describing GAS5 expression after LPS-induced inflammation was published. The authors
found that GAS5was downregulated in ATDC5 chondrocyte cells and its overexpression alleviated
LPS-induced injury [33]. Moreover, the expression levels of tumor necrosis factor (TNF)-↵, interleukin
(IL)-1 , IL-6, and IL-8were all significantly lowered byGAS5 overexpression. Themechanism proposed
by the authors is that GAS5 could modulate LPS-induced inflammatory damage through regulation of
Krüppel-like factor 2 expression and inhibition of the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-B) pathway [33].
In conclusion, the present study provides new information about the functional role of GAS5
in IBD patients: The lncRNA seems to be regulated by pro-inflammatory factors and could have an
important role in mediating tissue damage by modulating the expression ofMMP2 andMMP9. In the
future, the functional role of intestinal epithelium should be also investigated in this context using an
innovative platform such as intestinal organoids.
Moreover, this study provides new perspectives to stratify IBD phenotype by using as a single
measurement GAS5 expression in biopsies and supplies novel targets for future drug development in IBD.
4. Materials and Methods
4.1. Clinical Samples and Histologic Evaluation
Twenty-five IBD pediatric patients were enrolled at diagnosis at the gastroenterology department
of the Pediatric Clinic of IRCCS Burlo Garofolo in Trieste. For each patient, during colonoscopy,
two biopsies of the endoscopically inflamed and non-inflamed areas were collected. TRIzol® reagent
was used for RNA isolation. Protein analysis was also performed on inflamed and non-inflamed
biopsies obtained from three additional patients and immediately frozen on dry ice.
Histologic evaluation was performed for all patients enrolled in the study in which an adequate
sampling was obtained according to European Crohn’s and Colitis Organisation (ECCO) guidelines
(two biopsies for the five segments of the colon and terminal ileum) [34]. Histologic activity was
described using a predefined histologic inflammatory score and an architectural abnormalities score,
developed for a previous study [35].
Both inflammatoryandarchitectural scoreweredescribedwitha range from0 (absenceof inflammatory
activity) to 5 (maximal inflammatory activity) calculated considering three definedmorphological elements:
• active inflammation (neutrophils aggressive toward the glandular structures in the lamina propria)
(range from 0 to 3);
• crypt abscesses (range from 0 to 1);
• erosions and ulcerations (i.e., presence of granulation tissue) (range from 0 to 1).
Architectural abnormalities comprised three defined characteristics:
• glandular crypts alteration (range from 0 to 3);
• basal plasmacytosis (range from 0 to 1);
• epithelioid granulomas (range from 0 to 1).
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4.2. Ethical Considerations
Local ethical committee approval for the study (Protocol number: 2198; 17th September 2013) was
provided. The study was conducted in accordance with the principles outlined in the Declaration of
Helsinki, and the parents of all the participating children gave written informed consent before the
study began. Inclusion criteria were pediatric patients (5–18 years) with a diagnosis of CD or UC.
Exclusions criteria were: a) patients already treated with immunosuppressive drugs at the diagnosis;
b) disease requiring immediate surgical intervention; c) severe ulcerative colitis or toxic megacolon;
d) any of the following conditions: active infection; stool culture positive for enteric pathogens; tumors;
human immunodeficiency virus; transplanted organ; or non-controlled disease of the kidney, liver,
endocrine system, heart, blood, nervous system, or brain.
4.3. Total RNA Isolation
Total RNAwas extracted from biopsies and cells using TRIzol reagent (Thermo Scientific, Carlsbad,
CA, USA) according tomanufacturer’s instructions. The RNA concentration and purity were calculated
by Nano Drop instrument (NanoDrop 2000, EuroClone, Milan, Italy).
4.4. Quantitative Real-Time PCR
Expression levels ofGAS5,MMP2, andMMP9 geneswere evaluated by real-timeRT-PCRTaqMan®
analysis using the CFX96 real-time system-C1000 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA,
USA). The reverse transcription reaction was carried out with the High Capacity RNA-to-cDNA Kit
(Applied Biosystem, Foster City, CA, USA) and the real-time PCR was performed in triplicate using the
TaqMan® Gene Expression Assay to assess GAS5,MMP2, andMMP9mRNA expressions, according to
the manufacturer’s instructions. The thermal cycling conditions for TaqMan assays were as follows:
2 min at 50  C and 10 min at 95  C followed by 40 cycles at 95  C for 15 s and 60  C for 60 s.
The expression levels of GAS5, MMP2, and MMP9 were evaluated using the comparative Ct
method (2 DDCt method). The GAS5,MMP2, andMMP9 expression values were normalized using the
RPLP0 gene for studies encompassing tissues sampled from IBD patients [36] and the 18S or GAPDH
genes for the in vitro studies.
4.5. Immunoblotting
Inflamed and non-inflamed biopsies, obtained from the colon of IBD patients, were frozen,
homogenized and then lysed using a lysis buffer composed of Tris-HCl 10 mM pH 7.4, EDTA 100 mM,
NaCl 100 mM, SDS 0.1%, and protease inhibitor cocktail 1% (Sigma, Saint Louis, MO, USA). The protein
concentration was determined using the Bradford reagent (Sigma, Saint Louis, MO, USA). Samples
were run in a denaturing 10% polyacrylamide gel (Thermo Fisher Scientific, Carlsbad, CA, USA)
and were transferred to a PVDF membrane (Thermo Fisher Scientific, Carlsbad, CA, USA) that was
incubated overnight at 4  C with primary antibodies (anti-actin 1:10000 (42 kDa), anti-MMP9 1:1000
(92 kDa), and anti-MMP2 1:1000 (74 kDa); Sigma Saint Louis, MO, USA). The secondary antibodies
were an anti-mouse horseradish peroxidase (HRP) conjugated secondary antibody (Cell Signaling,
Danvers, MA, USA), diluted 1:40000 and an anti-rabbit HRP-conjugated secondary antibody (OriGene,
Herford, Germany) diluted 1:1000. The reaction was developed with a chemiluminescence reagent
containing luminol (Euroclone, Milan, Italy). Chemiluminescence was developed using LiteAblot®
TURBO (Euroclone, Milan, Italy) and exposed on Kodak Biomax film. MMP protein expression was
quantified using the ImageJ software, version 1.45s and was reported as percentage with respect to actin.
4.6. Cell Line and Stimulation
The THP1 human monocytic cell line (ATCC, TIB-202) was grown in RPMI 1640 medium
(Sigma-Aldrich, Saint Louis, MO, USA) supplemented with 10% fetal bovine serum 1% L-glutamine
200 mM, 1% penicillin 10,000 UI/mL, and streptomycin 10 mg/mL. The cell cultures were maintained
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according to standard procedures in a humidified incubator at 37  C with 5% CO2, and cell passage
was performed twice a week. THP1 cells were di↵erentiated into macrophages using 5 ng/mL of
phorbol-12-myristate 13-acetate (PMA, Sigma-Aldrich, Saint Louis, MO, USA) for two days. Monocytes
(THP1) and macrophages (THP1 + PMA) were stimulated with lipopolysaccharide (LPS; Sigma, Saint
Louis, MO, USA) 1 µg/mL for 3 h.
4.7. Transient Transfection
The full-length of GAS5 sequence was sub-cloned into pcDNA3.1 plasmid to generate
pcDNA3.1-GAS5. The empty pcDNA3.1 plasmid was used as negative control. Shortly before
transfection, 5 ⇥ 105 cells were seeded in twenty-four-well plates in 500 µL of complete medium. A total
of 1 µg of DNA was diluted in 3 µL of TransIT®-Jurkat transfection reagent (Mirus Bio, Madison, USA)
and, after 10 min of incubation, the complexes were added dropwise onto the cells according to the
manufacturer’s protocol. Twenty-four hours after transfection, cells were incubated with fresh RPMI
medium and then stimulated as described above. The analysis of GAS5 overexpression was carried
out after 24 h using real-time RT-PCR.
4.8. MMP2 and MMP9 Quantification
Cell culture supernatant obtained from THP1 cells, transfected with pcDNA3.1-GAS5 and then
exposed to LPS, PMA, and PMA + LPS as described above, was analyzed using Human MMP2 and
MMP9 ELISA Kit (Sigma-Aldrich, Saint Louis, MO, USA), according to the manufacturer’s instructions.
4.9. Statistical Analyses
Statistical analyses were performed using GraphPad Prism version 4.00. Since the distribution of
gene expression data in tissues obtained from patients was not parametric, data were normalized by
logarithmic transformation and paired t-test was applied. One-way ANOVA or two-way ANOVA
with Bonferroni post-test and t test were used for the in vitro studies of gene and protein expression;
p-values <0.05 were considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/21/
5280/s1.
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Abbreviations
lncRNA Long non-coding RNA
GAS5 Growth arrest–specific transcript 5
MMPs Matrix metalloproteinases
IBD Inflammatory bowel disease
CD Crohn’s disease
UC Ulcerative colitis
LPS Lipopolysaccharide
PMA Phorbol-12-myristate 13-acetate
ECM Extracellular matrix components
PCDAI Pediatric Crohn’s Disease Activity Index
PUCAI Pediatric Ulcerative Colitis Activity Index
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